A case of Fingolimod-associated Cryptococcal Meningitis
CONCLUSION: Albeit fingolimod associated cryptococcal meningitis is a rare event, Fingolimod therapy in patients with MS should be performed cautiously. Regular follow-ups may give rise to a timely diagnosis of probable fingolimod associated cryptococcal meningitis. Fingolimod therapy can lead to lymphocytopenia and various infections. We; therefore, suggest that intermittent blood lymphocyte counts as well as monitoring of clinical manifestations among MS patients treated with Fingolimod to avoid additional neurological and physical disabilities in these patients.PMID:35770404 | DOI:10.2174/1570162X20666220629124225 (Sour...
Source: Current HIV Research - June 30, 2022 Category: Infectious Diseases Authors: Ilad Alavi Darazam Mohammad Mahdi Rabiei Omid Moradi Farid Javandoust Gharehbagh Mehrdad Roozbeh Ramin Nourinia Firouze Hatami Maziar Shojaei Legha Lotfollahi Source Type: research
A case of Fingolimod-associated Cryptococcal Meningitis
CONCLUSION: Albeit fingolimod associated cryptococcal meningitis is a rare event, Fingolimod therapy in patients with MS should be performed cautiously. Regular follow-ups may give rise to a timely diagnosis of probable fingolimod associated cryptococcal meningitis. Fingolimod therapy can lead to lymphocytopenia and various infections. We; therefore, suggest that intermittent blood lymphocyte counts as well as monitoring of clinical manifestations among MS patients treated with Fingolimod to avoid additional neurological and physical disabilities in these patients.PMID:35770404 | DOI:10.2174/1570162X20666220629124225 (Sour...
Source: Current HIV Research - June 30, 2022 Category: Infectious Diseases Authors: Ilad Alavi Darazam Mohammad Mahdi Rabiei Omid Moradi Farid Javandoust Gharehbagh Mehrdad Roozbeh Ramin Nourinia Firouze Hatami Maziar Shojaei Legha Lotfollahi Source Type: research
020 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis: 6 study years
Conclusions
After 6 years of follow-up, rates of patients with CDP24 and risk of requiring a walking aid remained lower in earlier initiators of ocrelizumab (OCR-OCR) versus those initially receiving IFN (IFN-OCR), demonstrating maintained benefits of earlier treatment with ocrelizumab.
g.giovannoni@qmul.ac.uk (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - May 27, 2022 Category: Neurosurgery Authors: Giovannoni, G., Kappos, L., Seze, J. d., Hauser, S. L., Overell, J., Koendgen, H., Prajapati, K., Manfrini, M., Wang, Q., Wolinsky, J. S. Tags: Poster Presentations Source Type: research
Ocrelizumab for multiple sclerosis
CONCLUSIONS: For people with RRMS, ocrelizumab probably results in a large reduction in relapse rate and little to no difference in adverse events when compared with interferon beta-1a at 96 weeks (moderate-certainty evidence). Ocrelizumab may result in a large reduction in disability progression, treatment discontinuation caused by adverse events, number of participants with gadolinium-enhancing T1 lesions on MRI, and number of participants with new or enlarging T2-hyperintense lesions on MRI, and may result in little to no difference in serious adverse events (low-certainty evidence). For people with PPMS, ocrelizumab pr...
Source: Cochrane Database of Systematic Reviews - May 18, 2022 Category: General Medicine Authors: Mengbing Lin Jian Zhang Yueling Zhang Jiefeng Luo Shengliang Shi Source Type: research
Ocrelizumab for multiple sclerosis
CONCLUSIONS: For people with RRMS, ocrelizumab probably results in a large reduction in relapse rate and little to no difference in adverse events when compared with interferon beta-1a at 96 weeks (moderate-certainty evidence). Ocrelizumab may result in a large reduction in disability progression, treatment discontinuation caused by adverse events, number of participants with gadolinium-enhancing T1 lesions on MRI, and number of participants with new or enlarging T2-hyperintense lesions on MRI, and may result in little to no difference in serious adverse events (low-certainty evidence). For people with PPMS, ocrelizumab pr...
Source: Cochrane Database of Systematic Reviews - May 18, 2022 Category: General Medicine Authors: Mengbing Lin Jian Zhang Yueling Zhang Jiefeng Luo Shengliang Shi Source Type: research
Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart < sup > ® < /sup > Injector: Results of the Prospective Cohort Study REBIFLECT
CONCLUSION: Treatment adherence with the Rebismart® device was generally very high, consistent with other non-interventional studies. The first reflection talk supported by RebiSmart® induces excellent adherence, stabilized by repetition. Reflection to patients of subcutaneous interferon beta-1a treatment monitored by RebiSmart® is recommended to ensure prolonged strong treatment adherence.PMID:35428903 | DOI:10.1007/s12325-022-02100-w (Source: Adv Data)
Source: Adv Data - April 16, 2022 Category: Epidemiology Authors: Peter Rieckmann Tjalf Ziemssen Iris-Katarina Penner Alaleh Raji Torsten Wagner Joachim Richter Uwe K Zettl Source Type: research
Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart < sup > ® < /sup > Injector: Results of the Prospective Cohort Study REBIFLECT
CONCLUSION: Treatment adherence with the Rebismart® device was generally very high, consistent with other non-interventional studies. The first reflection talk supported by RebiSmart® induces excellent adherence, stabilized by repetition. Reflection to patients of subcutaneous interferon beta-1a treatment monitored by RebiSmart® is recommended to ensure prolonged strong treatment adherence.PMID:35428903 | DOI:10.1007/s12325-022-02100-w (Source: Adv Data)
Source: Adv Data - April 16, 2022 Category: Epidemiology Authors: Peter Rieckmann Tjalf Ziemssen Iris-Katarina Penner Alaleh Raji Torsten Wagner Joachim Richter Uwe K Zettl Source Type: research
Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart ® Injector: Results of the Prospective Cohort Study REBIFLECT
ConclusionTreatment adherence with the Rebismart® device was generally very high, consistent with other non-interventional studies. The first reflection talk supported by RebiSmart® induces excellent adherence, stabilized by repetition. Reflection to patients of subcutaneous interferon beta-1a treatment monitored by RebiSmart® is recommended to ensure prolonged strong treatment adherence. (Source: Advances in Therapy)
Source: Advances in Therapy - April 15, 2022 Category: Drugs & Pharmacology Source Type: research
Familial Cold Autoinflammatory Syndrome and Multiple Sclerosis
ConclusionsTo date, FCAS and possible association with MS has not been described. The case raises challenges in the diagnosis of concurrent disease processes. It also highlights that neurological sequelae should be considered in all spectrums of CAPS and distinctions should be made where possible with MS. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - March 28, 2022 Category: Neurology Authors: Syed B Ali,
Debajyoti Chaudhuri,
Deborah Field,
Pravin Hissaria Tags: CASE REPORT Source Type: research
POSC22 Demographics and Clinical DATA of a Real World Cohort of Multiple Sclerosis Patients Being Treated with Interferon Beta-1A SC in Portugal
To present initial Real World Evidence (RWE) from a patient support program registry of patients with multiple sclerosis currently being treated with interferon beta-1a s.c. in Portugal. (Source: Value in Health)
Source: Value in Health - January 1, 2022 Category: International Medicine & Public Health Authors: M Ribeiro, D Leal Source Type: research
IJERPH, Vol. 18, Pages 13261: Real-World Comparative Cost-Effectiveness Analysis of Different Classes of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in Saudi Arabia
uha M. Alkhawajah
The very fact that multiple sclerosis (MS) is incurable and necessitates life-long care makes it one of the most burdensome illnesses. The aim of this study was to compare the cost-effectiveness of orally administered medications (e.g., fingolimod, dimethyl fumarate, and teriflunomide), interferon (IFN)-based therapy, and monoclonal antibodies (MABs) (e.g., natalizumab and rituximab) in the management of relapsing-remitting multiple sclerosis (RRMS) in Saudi Arabia using real-world data. This was a retrospective cohort study in which patients with RRMS aged &ge;18 years without any other chron...
Source: International Journal of Environmental Research and Public Health - December 16, 2021 Category: Environmental Health Authors: Yazed AlRuthia Bander Balkhi Sahar Abdullah Alkhalifah Salman Aljarallah Lama Almutairi Miteb Alanazi Abdulmalik Alajlan Suliman M. Aldhafiri Nuha M. Alkhawajah Tags: Article Source Type: research
A 50 Year-Old Woman with A Delayed Diagnosis of Neuromyelitis Optica Spectrum Disorder: The Clinical Course and Serial Neuroimaging Findings
CONCLUSION: It is worthwhile to recheck the serum AQP4-IgG if the initial study showed negative result by using ELISA since CBA has higher sensitivity than previous study method.PMID:34841506 (Source: Acta Neurologica Taiwanica)
Source: Acta Neurologica Taiwanica - November 29, 2021 Category: Neurology Authors: Yu-Ju Huang Wen-Neng Chang Source Type: research
